{"id":1883,"date":"2019-05-17T12:00:03","date_gmt":"2019-05-17T10:00:03","guid":{"rendered":"https:\/\/www.arbios.org\/?p=1883"},"modified":"2019-05-17T12:01:32","modified_gmt":"2019-05-17T10:01:32","slug":"valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019","status":"publish","type":"post","link":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/","title":{"rendered":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019"},"content":{"rendered":"

VALBIOTIS is a French Research & Development company located at 3 sites in France including the Biopole Clermont-Limagne Riom site.
\nIts products are made for major players in the healthcare sector, in the field of metabolic diseases. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.<\/p>\n

VALEDIA\u00ae is the the most advanced product in the VALBIOTIS pipeline. The launch of VALEDIA\u00ae is planned for 2021, with a health claim for reducing the risk of type 2 diabetes.<\/p>\n

VALEDIA\u00ae intend to be the first natural and clinically proven solution specifically designed for prediabetics. VALEDIA\u00ae contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of type 2 diabetes.<\/p>\n

TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I\/II clinical study.
\nToday, VALEDIA\u00ae announces the completion of the international Phase IIA clinical study evaluating VALEDIA\u00ae in prediabetic subjects. VALBIOTIS will present the results of this study before 31 July 2019.<\/p>\n

The international Phase IIA, multicentric study evaluates the efficacy of TOTUM-63, the active ingredient of VALEDIA, reducing one or more of the 3 risk factors for type 2 diabetes, from the 3 criteria chosen by the Food and Drug Administration2 to obtain a healthclaim: insulin resistance, moderate fasting hyperglycemia and glucose intolerance.<\/p>\n

In addition to these prediabetes results, the study will evaluate other physiological parameters, including, for example, triglyceride regulation or intestinal microbiota composition. This additional data will help confirm the potential of VALEDIA\u00ae for other applications.<\/p>\n

 <\/p>\n

VALBIOTIS<\/strong><\/span>
\nBiop\u00f4le Clermont-Limagne<\/strong><\/span>
\nPhone. : +33 546 284 567
\nContact : Marc Delaunay |\u00a0marc.delaunay@valbiotis.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

VALBIOTIS is a French Research & Development company located at 3 sites in France including the Biopole Clermont-Limagne Riom site. Its products are made for major players in the healthcare sector, in the field of metabolic diseases. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALEDIA\u00ae […]<\/p>\n","protected":false},"author":2,"featured_media":1881,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nVALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios\" \/>\n<meta property=\"og:description\" content=\"VALBIOTIS is a French Research & Development company located at 3 sites in France including the Biopole Clermont-Limagne Riom site. Its products are made for major players in the healthcare sector, in the field of metabolic diseases. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALEDIA\u00ae […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Arbios\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-17T10:00:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-17T10:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png\" \/>\n\t<meta property=\"og:image:width\" content=\"763\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"arbios\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"arbios\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/\"},\"author\":{\"name\":\"arbios\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"headline\":\"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019\",\"datePublished\":\"2019-05-17T10:00:03+00:00\",\"dateModified\":\"2019-05-17T10:01:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/\"},\"wordCount\":280,\"image\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/valbiotis.png\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/\",\"name\":\"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/valbiotis.png\",\"datePublished\":\"2019-05-17T10:00:03+00:00\",\"dateModified\":\"2019-05-17T10:01:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/valbiotis.png\",\"contentUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/valbiotis.png\",\"width\":763,\"height\":458},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#website\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/\",\"name\":\"Arbios\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.arbios.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\",\"name\":\"arbios\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"caption\":\"arbios\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/","og_locale":"en_US","og_type":"article","og_title":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios","og_description":"VALBIOTIS is a French Research & Development company located at 3 sites in France including the Biopole Clermont-Limagne Riom site. Its products are made for major players in the healthcare sector, in the field of metabolic diseases. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALEDIA\u00ae […]","og_url":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/","og_site_name":"Arbios","article_published_time":"2019-05-17T10:00:03+00:00","article_modified_time":"2019-05-17T10:01:32+00:00","og_image":[{"width":763,"height":458,"url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png","type":"image\/png"}],"author":"arbios","twitter_card":"summary_large_image","twitter_misc":{"Written by":"arbios","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#article","isPartOf":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/"},"author":{"name":"arbios","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"headline":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019","datePublished":"2019-05-17T10:00:03+00:00","dateModified":"2019-05-17T10:01:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/"},"wordCount":280,"image":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/","url":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/","name":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019 - Arbios","isPartOf":{"@id":"https:\/\/www.arbios.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#primaryimage"},"image":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png","datePublished":"2019-05-17T10:00:03+00:00","dateModified":"2019-05-17T10:01:32+00:00","author":{"@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"breadcrumb":{"@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#primaryimage","url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png","contentUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2019\/05\/valbiotis.png","width":763,"height":458},{"@type":"BreadcrumbList","@id":"https:\/\/www.arbios.org\/en\/valbiotis-will-present-the-results-of-the-international-phase-iia-clinical-study-of-valedia-before-31-july-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.arbios.org\/en\/"},{"@type":"ListItem","position":2,"name":"VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA\u00ae before 31 July 2019"}]},{"@type":"WebSite","@id":"https:\/\/www.arbios.org\/#website","url":"https:\/\/www.arbios.org\/","name":"Arbios","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arbios.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b","name":"arbios","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","caption":"arbios"}}]}},"_links":{"self":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/comments?post=1883"}],"version-history":[{"count":1,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1883\/revisions"}],"predecessor-version":[{"id":1884,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1883\/revisions\/1884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media\/1881"}],"wp:attachment":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media?parent=1883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}